Peugeot posts net profit on cost savings

Article Abstract:

PSA Peugeot Citroen announced that it posted a 484 million euros ($529.3 million) net profit for the 1998 year. In 1997, the company posted a 422 million net loss. Peugeot's figures were improved a great deal by the vibrant automobile market in Western Europe and by major savings in costs in its automobile unit. The company also expressed optimism about 1999. In addition, Peugeot has been willing to consider possible acquisition or mergers.

Comment:

Posts 484 million euros ($529.3 million) net profit for the 1998 year

Motor vehicles and car bodies, Sales, profits & dividends, Motor Vehicles, Automobile and Light Duty Motor Vehicle Manufacturing, Finance, Abstract, Transportation equipment industry, Peugeot S.A.

---

Apotex launches generic Plavix, pressuring Bristol-Myers, Sanofi

Article Abstract:

Apotex Inc. of Canada has launched a generic knock off of the blood thinner Plavix. Product sales may cut into the market share of the original patent developers Sanofi-Aventis S.A. of France and Bristol-Myers Squibb Co. of the United States. Plavix is the second best selling drug worldwide.

United States, Canada, Product introduction, New Products/Services, Market share, Pharmaceutical preparations, Pharmaceutical industry, Bristol-Myers Squibb Co., BMY, Company market share, Apotex Inc., SNY, Sanofi-Aventis S.A.

---

Similar abstracts:

• Abstracts: Lufthansa posts dive in operating profit. Lufthansa warns it might cut estimate for '99 profit, sending stock down 1.8%
• Abstracts: BP posts 15% profit drop, gets $2.4 million fine. BP doubled profit in 2nd quarter energy prices increased and output rose in Russia amid technology advances
• Abstracts: Price wars hurt profits of French supermarkets. Tesco to expand land sales to fund growth; profit rises 22%
• Abstracts: Total's net profit declines 37% despite jump in energy prices. Total's net grew 7% in quarter as oil, gas production rose
• Abstracts: Roche's net rises strongly, buoyed by cancer drugs. Novartis buys American rights to antidepressant

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.